-
881
Key safety measures including adverse events.
منشور في 2025"…Waist circumference (mean change (MC) −2.23 cm; 95% CI [−3.98, −0.49]; <i>p</i> = 0.01), BMI (MC −0.49 kg/m<sup>2</sup>; 95% CI [−0.88, −0.10[; <i>p</i> = 0.01), and android fat mass measured by DXA (MC −167 g; 95% CI [−264, −71[; <i>p</i> < 0.001) decreased in the COCP group over the study period whilst there was no statistically significant changes in these parameters in the metformin only group when compared to baseline.. …"
-
882
-
883
-
884
-
885
-
886
-
887
-
888
-
889
-
890
-
891
-
892
Data.
منشور في 2025"…Participants in the progression group were younger (60.7 vs. 65.7 years, P = 0.015) and showed a larger BCVA change (0.20 vs. 0.04, P < 0.001) and greater ERM area decrease (34.2% vs. 11.7%, P < 0.001) during the follow-up period. …"
-
893
Baseline characteristics of patients.
منشور في 2025"…Participants in the progression group were younger (60.7 vs. 65.7 years, P = 0.015) and showed a larger BCVA change (0.20 vs. 0.04, P < 0.001) and greater ERM area decrease (34.2% vs. 11.7%, P < 0.001) during the follow-up period. …"
-
894
-
895
-
896
-
897
-
898
-
899
-
900